$4.8 Billion is the total value of RTW INVESTMENTS, LP's 60 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | ORCHESTRA BIOMED HLDGS INC | $100,169,182 | – | 5,118,507 | +100.0% | 2.09% | – | |
BRKR | New | BRUKER CORP | $93,610,043 | – | 1,187,342 | +100.0% | 1.95% | – |
SCPH | New | SCPHARMACEUTICALS INC | $29,911,436 | – | 3,297,843 | +100.0% | 0.62% | – |
VKTX | New | VIKING THERAPEUTICS INC | $16,650,000 | – | 1,000,000 | +100.0% | 0.35% | – |
New | MINERALYS THERAPEUTICS INC | $14,440,086 | – | 922,100 | +100.0% | 0.30% | – | |
New | JASPER THERAPEUTICS INC | $4,216,954 | – | 2,329,809 | +100.0% | 0.09% | – | |
New | YS BIOPHARMA CO LTDordinary shares | $545,744 | – | 341,090 | +100.0% | 0.01% | – | |
New | ROCKET PHARMACEUTICALS INC*w exp 09/02/202 | $38,500 | – | 350,000 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
MASIMO CORP | 32 | Q3 2023 | 5.8% |
LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
REGENXBIO INC | 30 | Q4 2022 | 10.8% |
AGENUS INC | 29 | Q2 2022 | 9.0% |
PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
ARGENX SE | 26 | Q3 2023 | 5.3% |
VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13D/A | 2024-04-17 |
SC 13D/A | 2024-03-01 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.